Meriofert Set

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed in fertility hormone therapy to address anovulation and to support controlled ovarian stimulation in assisted reproductive technologies. GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Set is a gonadotropin used in reproductive medicine to stimulate ovarian function. - Infertility due to anovulation: promotes follicular development and induces ovulation. - Controlled ovarian stimulation for assisted reproductive technologies: enhances follicle growth to optimize egg retrieval. - Ovulation induction in polycystic ovary syndrome: restores regular ovulatory cycles for conception.

Adverse reactions may occur with gonadotropin therapy and should be monitored.

Common Side Effects: - Injection site pain or erythema: mild local discomfort after subcutaneous administration. - Abdominal discomfort or bloating: transient gastrointestinal sensations. - Nausea or mild headache: occasional systemic symptoms. - Mild ovarian hyperstimulation syndrome: ovarian enlargement with mild fluid shift.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: marked ovarian enlargement, ascites, or thromboembolic complications. - Allergic reactions including anaphylaxis: rash, urticaria, respiratory distress. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Ectopic pregnancy: rare occurrence requiring prompt evaluation.

Careful patient assessment and monitoring are essential when using Meriofert Set. - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Ovarian monitoring: perform serial ultrasound to assess follicular response and prevent overstimulation. - Thromboembolic risk: evaluate history of clotting disorders before treatment. - Allergy assessment: screen for hypersensitivity to gonadotropin preparations. - Multiple pregnancy counseling: discuss the possibility of twins or higher‑order gestations. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may affect the efficacy or safety of Meriofert Set.

Major Interactions (Avoid): - GnRH antagonists: can diminish the stimulatory effect of FSH/LH therapy. - Oral contraceptives: suppress endogenous gonadotropin release, interfering with ovarian stimulation. - High‑dose estrogen therapy: may antagonize ovarian response to gonadotropins.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: monitor thyroid function as gonadotropins can influence metabolism. - Anticoagulants: increased vigilance for thrombotic events during ovarian hyperstimulation. - Diuretics: may alter fluid balance during stimulation, requiring observation.